Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen

被引：0
|
作者：
Yukiko Onishi
Hitoshi Ishii
Tomonori Oura
Masakazu Takeuchi
机构：
[1] The Institute for Adult Diseases,Department of Diabetology
[2] Asahi Life Foundation,undefined
[3] Nara Medical University,undefined
[4] Eli Lilly Japan K.K.,undefined
[5] Medical Development Unit—Japan,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Dulaglutide; Glycemic control; GLP-1 analog; Hypoglycemia; Insulin therapy; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：735 / 745
页数：10
相关论文
共 50 条
  • [31] Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index
    Shi, Yongquan
    Liu, Siying
    Zhu, Jiankun
    Hong, Tianpei
    JOURNAL OF DIABETES, 2021, 13 (04) : 353 - 357
  • [32] Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
    Kuang, Jian
    Zhu, Jiankun
    Liu, Siying
    Li, Quanmin
    DIABETES THERAPY, 2020, 11 (10) : 2329 - 2339
  • [33] Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
    Jian Kuang
    Jiankun Zhu
    Siying Liu
    Quanmin Li
    Diabetes Therapy, 2020, 11 : 2329 - 2339
  • [34] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Bech, Peter G.
    Persson, Sofie
    Leiter, Lawrence A.
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 537 - 550
  • [35] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Pierre Johansen
    Jonas Håkan-Bloch
    Aiden R. Liu
    Peter G. Bech
    Sofie Persson
    Lawrence A. Leiter
    PharmacoEconomics - Open, 2019, 3 : 537 - 550
  • [36] Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    Aroda, Vanita
    Bain, Stephen
    Cariou, Bertrand
    Piletic, Milivoj
    Rose, Ludger
    Bergan, Eirik Quamme
    Zacho, Jeppe
    Devries, J. Hans
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
  • [37] Impact of age on the efficacy and safety of once-weekly insulin icodec vs once-daily insulin in type 2 diabetes: ONWARDS 1-5
    Vianna, A. G. D.
    Desouza, C.
    Laugesen, C.
    Fragao-Marques, M.
    Nielsen, P. H.
    Shaikh, S.
    Lingvay, I.
    DIABETOLOGIA, 2024, 67 : S376 - S376
  • [38] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with Type 2 diabetes (SUSTAIN 4)
    Aroda, V. R.
    Bain, S. C.
    Cariou, B.
    Piletic, M.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    de Vries, J. H.
    DIABETIC MEDICINE, 2017, 34 : 146 - 146
  • [39] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    DeVries, J. H.
    Bain, S. C.
    Cariou, B.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    Aroda, V. R.
    DIABETOLOGIA, 2016, 59 : S76 - S77
  • [40] Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes Response
    Arslanian, Silva A.
    Cox, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (16): : 1530 - 1531
12345